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Mycoplasma Pneumoniae and Chlamydia Pneumoniae 
Seropositivity in Patients With Age-Related Macular 
Degeneration
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Abstract
Background: To determine a possible relation between Mycoplas-
ma pneumoniae (MP) or Chlamidia pneumoniae (CP) seropositiv-
ity and age-related macular degeneration (AMD).
Methods:  Sixty patients (20 wet AMD, 20 dry AMD and 20 non-
AMD controls) were included in the study. Serum samples were 
collected for analysis of IgM and IgG antibody seropositivity for 
CP  and  MP  by  enzyme-linked  immunosorbent  assay  (ELISA). 
Comparison of the distribution of seropositivity of these antibod-
ies among patients with wet and dry AMD, and controls was per-
formed. A prospective comparative clinical trial was applied.
Results:  There was no major difference in the distribution of IgM 
and IgG seropositivity to CP and MP in patients with wet and dry 
AMD, and in controls (p > 0.05).
Conclusions:  We found no significant association between MP as 
well as CP antibody titers and AMD. It seems that MP or CP infec-
tion is not a risk factor for AMD.
Keywords:  Mycoplasma pneumoniae; Chlamydia pneumoniae; 
Age-related macular degeneration; Serology
Introduction
Age-related macular degeneration (AMD) is a major cause 
of irreversible visual loss in developed countries in 65 years 
and older. Although the pathogenesis of AMD is not clearly 
understood, it has been considered that AMD is multifactori-
al disease. Risk factors associated with AMD include smok-
ing, diet, light exposure, advanced age, race, family history 
(genetics), body mass index, underlying cardiovascular dis-
ease, and systemic inflammatory or infectious diseases [1-3]. 
A number of clinical and experimental studies also suggest 
a role for inflammation or infection. The potential role of 
infectious agents as a trigger for inflammation in the patho-
genesis of AMD as well as systemic vascular diseases is a 
subject of continuing debate [4-6].
In recent studies, Cytomegalovirus (CMV), Chlamydia 
pneumoniae (CP), and Helicobacter pylori (HP) have been 
linked to AMD. The link between CP and AMD is still con-
troversial. Kalayoglu et al have demonstrated the presence 
of CP in choroidal neovascular membranes (CNVM) related 
with AMD and the serological association between CP infec-
tion and AMD [7, 8] whilst in two recent studies, Robman et 
al and Kessler et al failed to show an association between CP 
and AMD or AMD CNVM, respectively [9, 10]. There is no 
data in literature concerning the association between AMD 
pathogenesis  and  Mycoplasma  pneumonia  (MP),  another 
atypical bacterium. 
Mycoplasmas, which are the smallest and simplest self-
replicating microorganisms, can exist as a persistent asymp-
tomatic infection, resulting in chronic inflammation as well 
as CP [11, 12]. MP is a significant respiratory pathogen in 
persons of all ages, causing respiratory disease, and it may 
induce clinically significant manifestations in extra-pulmo-
nary sites by direct invasion and/or immunologic effects. 
Macrophage activation, cytokine induction, and super-anti-
gen properties are some factors related to the pathogenity of 
Mycoplasmas [11-14]. In recent studies, the association of 
MP and CP has been described in pneumonia, astma, aortic 
stenosis, coronary atherosclerosis, and stroke or in immuno-
deficient patients [15-20]. In addition, it is considered that 
co-infections with CP in association with MP potentiate the 
virulence of both agents. Therefore, when circulating anti-
bodies of both these two agents are present in patients with 
AMD, they may increase each other’s pathogenicity [21, 22].
Therefore, we hypothesized that infection or postinfec-
tion with MP may be associated with AMD and we purposed 
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to determine this possible association.
 
Patients and Methods
This pilot study was designed as a prospective case-control 
study and 20 patients with dry AMD (Group 1), 20 patients 
with wet AMD (Group 2) and 20 subjects age- and sex-
matched and without AMD (Group 3) were included in the 
study. All  patients  underwent  a  complete  ophthalmologic 
and general examination. The protocol for the study was re-
viewed and approved by the institutional review board. The 
tenets of the Helsinki declaration were followed throughout 
the study. Informed consent was obtained from each sub-
ject including detailed explanation of all procedures before 
participation in the study. A staff retina specialist classified 
AMD into nonneovascular or neovascular stages of disease.
Inclusion criteria
In group 1, the patients with dry (nonneovascular) AMD 
characterized  by  macular  drusen  or  the  presence  of  geo-
graphic atrophy without choroidal neovascularization (NV) 
or scarring documented by color fundus imaging, Fundus 
Fluorescein Angiography (FFA) and Optic Coherence To-
mography (OCT). 
In group 2, the patients with wet AMD with CNVM or 
disciform scar documented by FFA and OCT. 
In  group  3,  control  subjects  that  are  sex-  and  age-
matched  subjects  included  patients  presenting  for  routine 
eye examination with or without other ocular disorders, but 
without evidence of drusen, retina pigment epithelial chang-
es or choroidal neovascularization. 
The participants with diabetes mellitus, ocular or sys-
temic  infection  and  inflammation,  any  hematological  and 
immune  disease,  malignancy,  hypergammaglobulinemia, 
connective tissue disease, history of myocardial infarction 
and coronary artery disease, or history of the usage of the 
drug that could influence serum immunoglobulin levels and 
previous laser treatment or intravitreal injection were ex-
cluded from the study.
Serological assay   
Peripheral venous blood (10 ml) was collected from patients 
and healthy controls by venipuncture. The serum was sepa-
rated and stored frozen at -20 oC. Samples were encoded, and 
laboratory personnel were masked to clinical information on 
the patients. Serological analysis as described in the follow-
ing subsections was made by same personnel. 
Qualitative immunoenzymatic determination of human 
CP IgG and IgM in serum were made using Novatec/Immu-
nodiagnostica GmbH Germany (product No: CHLM0070, 
CHLG0070) on automatised ELISA system. Microtiter strip 
wells are precoated with CP antigens to bind corresponding 
antibodies of the specimen. After washing the wells to re-
move all unbound sample material horseradish peroxidase 
(HRP) labeled anti-human IgG (IgM) conjugate is added. 
This conjugate binds to the captured Chlamydia specific an-
tibodies. The immune complex formed by the bound con-
jugate is visualized by adding tetrametilbenzidine substrate 
which gives a blue reaction product. The intensity of this 
product is proportional to the amount of Chlamydia specific 
IgG (IgM) antibodies in the specimen. Sulphuric acid is add-
ed to stop the reaction. This produces a yellow endpoint col-
or. Absorbance at 450 nm infrared was read using an ELISA 
micro well plate reader. 
The absorbance of all wells at 450 nm was measured and 
the absorbance values for each control and patients samples 
was recorded for identification absorbance distribution. The 
cut-off value was calculated according to absorbance value. 
Samples were considered positive if the absorbance value is 
higher than 10% over the cut-off. All results were given as a 
NovaTec Units (NTU) (Cut-off:10 NTU). 
Quantitative tests for detection of human antibodies IgG 
and IgM in serum against MP (Virion/Serion GmbH Ger-
many (product No: ESR127G and ESR127M) ELISA kit. 
Antibodies activities were given in U/ml. For MP IgG 
calculation was interpreted positive results >30 U/ml, bor-
derline results 20 - 30 U/ml and negative results < 20 U/ml, 
and for IgM was positive results >17 U/ml, borderline results 
13 - 17 U/ml, negative results <13 U/ml. All ELISA reactions 
were performed according to manufacturer’s instructions on 
Dynex 1DXC-1381 (USA) full automatic ELISA system.
Statistical analysis
Statistical analysis was performed using the Statistical Pack-
age for the Social Sciences version 13.0 (SPSS, Inc., Chi-
cago, IL, USA). The Student t test or chi-square test was 
used to compare nominal and categorical variables among 
the study groups, respectively. Results were given as means 
± standard deviations. P value less than 0.05 was considered 
as statistically significant. 
 
Results
The subjects included 13 men (65%) and 7 women (35%) in 
Group 1; 12 men (60%) and 8 women (40%) in Group 2; 10 
men (50%) and 10 women (50%) in Group 3. The mean ages 
of the Group 1, Group 2 and Group 3 were 68.9 ± 4.99 years 
(range, 56 to 78 years), 65.85 ± 4.91 years (range, 58 to 74 
years), 66.50 ± 4.84 years (range, 55 to 80 years), respective-
ly. The patient and control groups were matched for age and 
sex and there was no statistically significant difference with 
regard to age and gender among the groups (p > 0.05). The 
demographical data in the study groups are shown in Table 1.
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None of 60 patients in the study groups had positive for 
Ig M antibody titers to CP. Two (10%) of 20 patients with 
wet AMD had positive for IgG antibody titers to CP, com-
pared with none of 20 patients with dry AMD and none of 20 
controls. There was no major difference in the distribution of 
IgM and IgG titers for CP in wet and dry AMD (p > 0.05).
Similarly, there was no major difference in the distribu-
tion of IgM and IgG titers for MP in wet and dry AMD, and 
in controls (p > 0.05). All of the patients with wet AMD and 
dry AMD had negative for IgM antibody titers to MP whilst 
19 (95%) of 20 controls had negative. Borderline IgM titers 
to MP were only one in the controls. One (5%) of 20 pa-
tients with wet AMD had positive for IgG antibody titers to 
MP, compared with two (10%) of 20 dry AMD patients. One 
(5%) of 20 controls had positive. Borderline IgG titers to MP 
were observed in three patients (15%) in wet AMD group but 
only one (5%) in each of dry AMD and control group. IgM 
and IgG seropositivities to CP and MP in the study groups 
are shown in Table 2.
The mean serum IgM titers for CP in patients with dry 
AMD (Group 1), wet AMD (Group 2) and in the controls 
(Group 3) were 2.09 ± 1.56, 1.27 ± 1.18 and 1.48 ± 0.53 
NTU/mL, respectively. The mean serum IgG titers for CP 
in patients with dry AMD (Group 1), wet AMD (Group 2) 
and in the controls (Group 3) were 5 ± 4.72, 4.29 ± 3.51 and 
3.30 ± 2.06 NTU/mL, respectively. There was no significant 
difference among the serum IgM and IgG titers of the study 
groups (p > 0.05). 
The mean serum IgM titers for MP in patients with dry 
AMD (Group 1), wet AMD (Group 2) and in the controls 
(Group 3) were 3.13 ± 1.03, 4.13 ± 1.99 and 4.13 ± 2.63 
mlU/mL, respectively. The mean serum IgG titers for MP in 
patients with dry AMD (Group 1), wet AMD (Group 2) and 
in the controls (Group 3) were 9.95 ± 9.89, 12.99 ± 8.75 and 
15.78 ± 8.32 U/mL, respectively. There was no significant 
difference among the serum IgM and IgG titers of the study 
groups (p > 0.05).
Discussion
  
A number of studies in humans and animals suggest that in-
flammation or infection may play a role in the pathogenesis 
of AMD. There is some evidence the relation between AMD 
and infections due to CMV, HP or CP [7-10, 23, 24]. Kalayo-
glu and Robman and their coworkers demonstrated that se-
Group (n) Mean Age (range) Gender (%)
Dry AMD (20) 68.90 ± 4.99 years (56 -78) 13 men (65%), 7 women (35%)
Wet AMD (20) 65.85 ± 4.91 years (58 -74) 12 men (60%), 8 women (40%)
Non-AMD controls (20) 66.50 ± 4.84 years (55 - 80) 10 men (50%), 10 women (50%)
Table 1. Demographical Data in the Study Groups
Group CP  IgM
Seropositivity (%)
CP  IgG
Seropositivity (%)
MP  IgM
Seropositivity (%)
MP  IgG
Seropositivity (%)
Group 1 (n = 20) Positive: 0 (0%)
Negative: 20 (100%)
Positive: 0 (0%)
Negative: 20 (100%)
Positive: 0 (0%)
Borderline: 0 (0%)
Negative: 20 (100%)
Positive: 2 (10%)
Borderline: 1(5%)
Negative: 17 (85%)
Group 2 (n = 20) Positive: 0 (0%)
Negative: 20 (100%)
Positive: 2 (10%)
Negative: 18 (90%)
Positive: 0 (0%)
Borderline: 0 (0%)
Negative: 20 (100%)
Positive: 1(5%)
Borderline: 3(15%)
Negative: 16(80%)
Group 3 (n = 20) Positive: 0 (0%)
Negative: 20 (100%)
Positive: 0 (0%)
Negative: 20 (100%)
Positive: 0 (0%)
Borderline: 1 (5%)
Negative: 19 (95%)
Positive: 1(5%)
Borderline: 1(5%)
Negative: 18(90%)
Table 2. IgM and IgG Seropositivities to CP and MP (%)
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rum antibodies for CP proteins are associated with increased 
risk for the development and progression of AMD [7, 10]. In 
another study, Kalayoglu et al. demonstrated the presence of 
CP in AMD CNVM when compared to the eyes with AMD 
without CNVM and non-AMD eyes [8]. They reported that 
macrophages may produce VEGF after infection with CP. 
In addition, Miller et al investigated the possible associa-
tion between AMD and CP, HP, and CMV, as these agents 
are known to cause chronic infection and inflammation and 
CMV has been shown in animal models to accelerate the 
development of atherosclerosis. Miller et al found a signifi-
cant association between high anti-CMV IgG titers and wet 
AMD compared with control and dry AMD patients. How-
ever, they did not find a difference in the distribution of titers 
for CP and HP in wet and dry AMD patients. They proposed 
that CMV-infected macrophages and endothelial cells might 
release  increased  amounts  of  proinflammatory  cytokines 
that could cause the development of CNVM [23].
In another study, Ishida et al also found significantly 
elevated anti-CP IgG antibodies in patients with wet AMD 
compared with control subjects [24]. In contrast to these 
studies, two recent studies by Robman et al and Kessler et al 
failed to show an association between CP and AMD or AMD 
CNV, respectively [9, 10].
In our study, we expected elevation in CP antibodies in 
patients with specially wet AMD. However, distributions of 
CP antibodies were not found to be significantly different 
between patients with AMD and controls. These findings are 
contrary to those in the previous reports which demonstrated 
an association between CP infection and AMD. Our data 
supports the controversial role of CP in AMD pathogenesis. 
To the best of our knowledge, this is the first report in-
vestigating the possible association between MP and AMD. 
In present study, we could not find a relation between AMD 
and MP. The insignificant results concerning with serology 
of MP in our study may be due to local inflammation. Thus, 
the  histopathological  or  immunohistochemical  studies  in 
AMD CNVMs would be providing to understand the pos-
sible role of MP in AMD pathogenesis. 
Although sample size of our study may be a limitation 
in this study, sufficient data to support this relationship could 
not be obtained. But it seems that MP or CP infection is not 
be related with the development of AMD. The long-term and 
larger studies in the series will contribute to verification of 
this relationship.
Acknowledgments 
Those involved in conducting the study would like to thank 
those who assisted with the collection of data, typing, edit-
ing of manuscript, its preparation, for review, and approval 
of the final manuscript. The authors report no conflicts of 
interest in this work.
References
1.  Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis 
AP. Age-related macular degeneration: etiology, patho-
genesis,  and  therapeutic  strategies.  Surv  Ophthalmol 
2003;48(3):257-293.
2.  Clemons TE, Milton RC, Klein R, Seddon JM, Ferris 
FL, 3rd. Risk factors for the incidence of Advanced Age-
Related Macular Degeneration in the Age-Related Eye 
Disease Study (AREDS) AREDS report no. 19. Oph-
thalmology 2005;112(4):533-539.
3.  Scholl HP, Fleckenstein M, Charbel Issa P, Keilhauer C, 
Holz FG, Weber BH. An update on the genetics of age-
related  macular  degeneration.  Mol  Vis  2007;13(196-
205.
4.  Patel M, Chan CC. Immunopathological aspects of age-
related  macular  degeneration.  Semin  Immunopathol 
2008;30(2):97-110.
5.  Kijlstra  A,  La  Heij  E,  Hendrikse  F.  Immunological 
factors  in  the  pathogenesis  and  treatment  of  age-re-
lated  macular  degeneration.  Ocul  Immunol  Inflamm 
2005;13(1):3-11.
6.  Penfold PL, Madigan MC, Gillies MC, Provis JM. Im-
munological and aetiological aspects of macular degen-
eration. Prog Retin Eye Res 2001;20(3):385-414.
7.  Kalayoglu MV, Galvan C, Mahdi OS, Byrne GI, Man-
sour  S.  Serological  association  between  Chlamydia 
pneumoniae infection and age-related macular degen-
eration. Arch Ophthalmol 2003;121(4):478-482.
8.  Kalayoglu  MV,  Bula  D,  Arroyo  J,  Gragoudas  ES, 
D’Amico  D,  Miller  JW.  Identification  of  Chlamydia 
pneumoniae within human choroidal neovascular mem-
branes secondary to age-related macular degeneration. 
Graefes Arch Clin Exp Ophthalmol 2005;243(11):1080-
1090.
9.  Kessler W, Jantos CA, Dreier J, Pavlovic S. Chlamydia 
pneumoniae is not detectable in subretinal neovascular 
membranes in the exudative stage of age-related macular 
degeneration. Acta Ophthalmol Scand 2006;84(3):333-
337.
10.  Robman L, Mahdi OS, Wang JJ, Burlutsky G, Mitchell 
P, Byrne G, Guymer R, et al. Exposure to Chlamydia 
pneumoniae infection and age-related macular degener-
ation: the Blue Mountains Eye Study. Invest Ophthalmol 
Vis Sci 2007;48(9):4007-4011.
11.  Waites  KB, Talkington  DF.  Mycoplasma  pneumoniae 
and its role as a human pathogen. Clin Microbiol Rev 
2004;17(4):697-728, table of contents.
12.  Waites KB, Balish MF, Atkinson TP. New insights into 
the pathogenesis and detection of Mycoplasma pneu-
moniae infections. Future Microbiol 2008;3(6):635-648.
13.  Razin  S,  Yogev  D,  Naot  Y.  Molecular  biology  and 
pathogenicity of mycoplasmas. Microbiol Mol Biol Rev 
     87                                   88J Clin Med Res  •  2010;2(2):85-89    Atypical Pneumoniae and AMD
Articles © The authors   |   Journal compilation © J Clin Med Res and Elmer Press™   |   www.jocmr.org
1998;62(4):1094-1156.
14.  Abdelrahman YM, Belland RJ. The chlamydial devel-
opmental cycle. FEMS Microbiol Rev 2005;29(5):949-
959.
15.  Goyal P, Kalek SC, Chaudhry R, Chauhan S, Shah N. 
Association of common chronic infections with coro-
nary artery disease in patients without any conventional 
risk factors. Indian J Med Res 2007;125(2):129-136.
16.  Momiyama Y, Ohmori R, Taniguchi H, Nakamura H, 
Ohsuzu  F.  Association  of  Mycoplasma  pneumoniae 
infection  with  coronary  artery  disease  and  its  inter-
action  with  chlamydial  infection.  Atherosclerosis 
2004;176(1):139-144.
17.  Higuchi M, Castelli JB, Aiello VD, Palomino S, Reis 
MM, Sambiase NV, Fukasawa S, et al. Great amount 
of C.pneumoniae in ruptured plaque vessel segments at 
autopsy. A comparative study with stable plaques. Arq 
Bras Cardiol 2000;74(2):149-151.
18.  Higuchi ML, Sambiase N, Palomino S, Gutierrez P, De-
marchi LM, Aiello VD, Ramires JA. Detection of My-
coplasma pneumoniae and Chlamydia pneumoniae in 
ruptured atherosclerotic plaques. Braz J Med Biol Res 
2000;33(9):1023-1026.
19.  Ngeh J, Goodbourn C. Chlamydia pneumoniae, Myco-
plasma pneumoniae, and Legionella pneumophila in el-
derly patients with stroke (C-PEPS, M-PEPS, L-PEPS): 
a case-control study on the infectious burden of atypical 
respiratory pathogens in elderly patients with acute cere-
brovascular disease. Stroke 2005;36(2):259-265.
20.  Higuchi  Mde  L,  Higuchi-Dos-Santos  MH,  Pierri  H, 
Palomino S, Sambiase NV, Ramires JA, Wajngarten M. 
Mycoplasma pneumoniae and Chlamydia pneumoniae 
in calcified nodules of aortic stenotic valves. Rev Inst 
Med Trop Sao Paulo 2002;44(4):209-212.
21.  Stacey A, Bradlow A. Arcanobacterium haemolyticum 
and  Mycoplasma  pneumoniae  co-infection.  J  Infect 
1999;38(1):41-42.
22.  Meijer A, van Der Vliet JA, Roholl PJ, Gielis-Proper SK, 
de Vries A, Ossewaarde JM. Chlamydia pneumoniae in 
abdominal aortic aneurysms: abundance of membrane 
components in the absence of heat shock protein 60 and 
DNA. Arterioscler Thromb Vasc Biol 1999;19(11):2680-
2686.
23.  Miller DM, Espinosa-Heidmann DG, Legra J, Dubovy 
SR, Suner IJ, Sedmak DD, Dix RD, et al. The associa-
tion of prior cytomegalovirus infection with neovascu-
lar age-related macular degeneration. Am J Ophthalmol 
2004;138(3):323-328.
24.  Ishida O, Oku H, Ikeda T, Nishimura M, Kawagoe K, 
Nakamura K. Is Chlamydia pneumoniae infection a risk 
factor for age related macular degeneration? Br J Oph-
thalmol 2003;87(5):523-524.
 
     89                                   